421 related articles for article (PubMed ID: 12053601)
41. Mucolytics, expectorants, and mucokinetic medications.
Rubin BK
Respir Care; 2007 Jul; 52(7):859-65. PubMed ID: 17594730
[TBL] [Abstract][Full Text] [Related]
42. [Antioxidative features of ambroxol--usefulness in COPD].
Nowak D
Pneumonol Alergol Pol; 2001; 69(9-10):590-3. PubMed ID: 11928667
[No Abstract] [Full Text] [Related]
43. [Clinical trial of N-cyclohexyl-N-methyl(-2-amino-3,5-dibromobenzyl)-ammonium chloride associated with antibiotics in therapy of chronic bronchopneumopathies].
Quilici G; Da Porto R
Clin Ter; 1970 Sep; 54(6):495-517. PubMed ID: 5527647
[No Abstract] [Full Text] [Related]
44. Role of mucolytics in wet cough.
Dhar R
J Assoc Physicians India; 2013 May; 61(5 Suppl):23-7. PubMed ID: 24490447
[No Abstract] [Full Text] [Related]
45. [Acetylcysteine in chronic obstructive pulmonary disease. Secretolytic, antioxidant or placebo?].
Randerath W; Galetke W
Med Monatsschr Pharm; 2003 Nov; 26(11):375-8. PubMed ID: 14652922
[No Abstract] [Full Text] [Related]
46. Do mucolytics help in chronic bronchitis and asthma?
Drug Ther Bull; 1984 Apr; 22(8):29-31. PubMed ID: 6714085
[No Abstract] [Full Text] [Related]
47. [Comparative studies on the mucolytic effectiveness of Mucosolvin oral and Mucosolvin inhalant].
Fischer JF; Scheuler D
Z Erkr Atmungsorgane; 1986; 167(1-2):96-102. PubMed ID: 3765720
[TBL] [Abstract][Full Text] [Related]
48. The SH-metabolite I of erdosteine, a mucolytic drug, enhances the inhibitory effect of salbutamol on the respiratory burst of neutrophils.
Dal Sasso M; Bovio C; Culici M; Fonti E; Braga PC
Drugs Exp Clin Res; 2002; 28(4):147-54. PubMed ID: 12512232
[TBL] [Abstract][Full Text] [Related]
49. [Bronchial mucus modifiers, antioxidants and antiproteases].
Polu JM; Chabot F; Wallaert B
Rev Mal Respir; 1993; 10(2):87-100. PubMed ID: 8502804
[No Abstract] [Full Text] [Related]
50. Pharmacotherapy of impaired mucociliary clearance in non-CF pediatric lung disease. A review of the literature.
Boogaard R; de Jongste JC; Merkus PJ
Pediatr Pulmonol; 2007 Nov; 42(11):989-1001. PubMed ID: 17902149
[TBL] [Abstract][Full Text] [Related]
51. Biofilm-dependent airway infections: a role for ambroxol?
Cataldi M; Sblendorio V; Leo A; Piazza O
Pulm Pharmacol Ther; 2014 Aug; 28(2):98-108. PubMed ID: 24252805
[TBL] [Abstract][Full Text] [Related]
52. [Experience with a combination of auxiloson and bisolvon is diseases of the respiratory tract following multilocular findings].
Mertens H
Z Allgemeinmed; 1969 Sep; 45(26):1222-5. PubMed ID: 5374621
[No Abstract] [Full Text] [Related]
53. [The cleaning system of the airways: physiology, pathophysiology and effects of ambroxol].
Wunderer H; Morgenroth K; Weis G
Med Monatsschr Pharm; 2009 Feb; 32(2):42-7. PubMed ID: 19263911
[TBL] [Abstract][Full Text] [Related]
54. [New treatment possibilities in obstructive respiratory tract diseases].
Rambauske F
Wien Med Wochenschr; 1971 Jan; 121(3):36-7. PubMed ID: 5545426
[No Abstract] [Full Text] [Related]
55. Mucoactive medications and airway disease.
Majima Y
Paediatr Respir Rev; 2002 Jun; 3(2):104-9. PubMed ID: 12297055
[TBL] [Abstract][Full Text] [Related]
56. Mucolytic agents.
Br Med J; 1971 Jun; 2(5761):581-2. PubMed ID: 5579199
[No Abstract] [Full Text] [Related]
57. Advances in the treatment of respiratory disorders.
Kilpatrick GS
Practitioner; 1971 Oct; 207(240):460-7. PubMed ID: 4943694
[No Abstract] [Full Text] [Related]
58. Erdosteine for COPD exacerbations.
Drug Ther Bull; 2008 Oct; 46(10):79-80. PubMed ID: 18832259
[TBL] [Abstract][Full Text] [Related]
59. [Respiratory diseases and oxidants].
Leuenberger P
Schweiz Med Wochenschr; 1994 Jan; 124(4):129-35. PubMed ID: 8128194
[TBL] [Abstract][Full Text] [Related]
60. Advances in the treatment of respiratory disorders.
Heaf PJ
Practitioner; 1969 Oct; 203(216):453-9. PubMed ID: 4311091
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
